ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Offers Grants For Conferences

May 1, 1987

House and Senate Appropriators Pledge to Increase Biomedical Research Funding.

March 5, 1999

Advances In Cancer Control Meeting Is Set For March 22

February 3, 1989

NCI Develops Plan For Specialized Centers, But Funding $67.5M Program Depends On New $$

July 5, 1991

Chabner, FDA’s Temple continue disagreement Over Drug Approval

February 10, 1989

Competing Strategies For Breast Cancer? Brinker Tries to Ensure acceptance Of Report, Visco Urges Broad Effort

October 8, 1993